BioAdaptives, Inc. (OTC: BDPT) has announced the launch of MyndRenew™, a nighttime dietary supplement designed to support sleep quality and the brain’s overnight recovery processes. The product addresses what the company describes as a critical gap in cognitive health, as more than one-third of U.S. adults report insufficient sleep, according to the press release.
MyndRenew is part of the MyndSystem™ platform, which targets full 24-hour cognitive support with formulations tailored to both daytime performance and nighttime recovery. The supplement includes 13 ingredients selected from published scientific literature, including magnesium glycinate, apigenin, PEA (palmitoylethanolamide), and lion’s mane mushroom extract. These ingredients are aimed at supporting sleep pathways, cellular repair, stress regulation, and neuroprotection.
The launch of MyndRenew complements the company’s existing daytime product, MyndMed™, with both products positioned to address distinct physiological demands across the daily cycle. This dual-product approach highlights a growing trend in the nutraceutical industry toward chrononutrition—tailoring supplement regimens to the body’s circadian rhythms.
The significance of this launch lies in the widespread prevalence of sleep deprivation in the United States. The Centers for Disease Control and Prevention (CDC) has previously stated that insufficient sleep is a public health epidemic, linked to chronic conditions such as heart disease, diabetes, and cognitive decline. By focusing on overnight recovery, BioAdaptives aims to address the restorative functions of sleep that are critical for memory consolidation, toxin clearance, and neural repair.
BioAdaptives develops and markets science-based health and wellness products for human and animal use, with formulations rooted in published research across nutrition, adaptogens, and cellular health. The company emphasizes a focus on supporting normal physiological function.
For more information about BioAdaptives and its products, visit www.bioadaptives.com. The full press release is available at https://ibn.fm/jubib.
